Edralbrutinib

Overview

Edralbrutinib (TG-1701) is a highly selective, orally available irreversible BTK inhibitor, with an EC 50 of 6.70 nM and a K d of 3 nM against human BTK . Edralbrutinib inhibits downstream signaling of the B cell receptor , induces dephosphorylation of Ikaros Ser442/445, promotes nuclear exclusion of Ikaros, attenuates Ikaros gene signatures, and exerts anti-tumor activity. Edralbrutinib can be used in research related to B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > Btk

Product Information

• Catalog No.: HY-137438
• CAS No.: 1858206-58-2
• Molecular Formula: C26H21F2N5O3
• Molecular Weight: 489.47
• Purity: 99.75%
• Storage: 4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
• Solubility: ≥ 1.25 mg/mL (2.55 mM); Clear solution
• Availability: In-stock

Source

Original product source